Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, when TP53 is mutated, chemotherapy-induced inactivation of this pathway and the accumulation of LRPPRC and MDR1 promote drug resistance.195”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [195]
In the citing paper
“Wild-type p53 inhibits LRPPRC expression via miR-34a, further reducing MDR1 expression.”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · cited 1×
“Chemotherapy based on 5-fluorouracil (5FU) is the main treatment for CRC [2].”
Background5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518 · cited 1×
“Among them, miR-34a was previously reported to be associated with the P53 signalling pathway [34].”
BackgroundBlondy, S., David, V., Verdier, M., Mathonnet, M., Perraud, A., & Christou, N. (2020) · Cancer Science · doi:10.1111/cas.14532 · Cited by 507
LRPPRC-mediated folding of the mitochondrial transcriptome
Siira, S. J., Spåhr, H., Shearwood, A.-M. J., Ruzzenente, B., Larsson, N.-G., Rackham, O., & Filipovska, A. (2017) · Nature Communications · doi:10.1038/s41467-017-01221-z · Cited by 123
TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression
Wang, S., Zhang, Y., Huang, J., Wong, C. C., Zhai, J., Li, C., Wei, G., Zhao, L., Wang, G., Wei, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3614 · Cited by 104
Self-citation
Research works printed but not linked: 30
- Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. · DOI · Paper page
- Ramos A, Hemann MT. Drugs, bugs, and cancer: Fusobacterium nucleatum promotes chemoresistance in colorectal. Cancer Cell 2017;170:411–3.
- Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol: Off J Am Soc Clin Oncol. 2007;25:773–80. · DOI · Paper page
- van der Stok EP, Spaander MCW, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol. 2017;14:297–315. · DOI · Paper page
- Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49–53. · DOI · Paper page
- Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003;21:271–6. · DOI · Paper page
- Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23:7518–28. · DOI · Paper page
- Stiewe T, Haran T. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat. 2018;38:27–43. · DOI
- Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13:1017–26. · DOI · Paper page
- Cao X, Hou J, An Q, Assaraf YG, Wang X. Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 2020;49:100671 · DOI · Paper page
- Hou J, Wang F, McKeehan WL. Molecular cloning and expression of the gene for a major leucine-rich protein from human hepatoblastoma cells (HepG2). In vitro cellular & developmental biology. Animal 1994;30a:111–4.
- Mootha V, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA. 2003;100:605–10. · DOI · Paper page
- Schweitzer C, Matthews J, Madson C, Donnellan M, Cerny R, Belshan M. Knockdown of the cellular protein LRPPRC attenuates HIV-1 infection. PLoS ONE. 2012;7:e40537. · DOI
- Jiang X, Li X, Huang H, Jiang F, Lin Z, He H, et al. Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer 2014;120:1228–36. · DOI
- Cui J, Wang L, Ren X, Zhang Y, Zhang H. LRPPRC: a multifunctional protein involved in energy metabolism and human disease. Front Physiol. 2019;10:595. · DOI
- Chen Z, Chen X, Xie R, Huang M, Dong W, Han J, et al. DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol Ther: J Am Soc Gene Ther. 2019;27:326–41. · DOI
- Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto L. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein. Nucleic Acids Res. 2004;32:3864–76. · DOI
- Hu Y, Cui J, Jin L, Su Y & Zhang X. LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating MDR1 expression. Oncol Rep. 2021;45:4. · doi:10.3892/or.2021.7955
- Corrêa S, Binato R, Du Rocher B, Ferreira G, Cappelletti P, Soares-Lima S, et al. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter. Epigenetics 2014;9:1172–83. · DOI
- Corrêa S, Pizzatti L, Du Rocher B, Mencalha A, Pinto D, Abdelhay E. A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line. Proteome Sci. 2012;10:23. · DOI
- Zhou W, Sun G, Zhang Z, Zhao L, Xu L, Yuan H, et al. Proteasome-independent protein knockdown by small-molecule inhibitor for the undruggable lung adenocarcinoma. J Am Chem Soc. 2019;141:18492–9. · DOI
- McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem. 2010;110:1187–94. · DOI
- Kisim A, Atmaca H, Cakar B, Karabulut B, Sezgin C, Uzunoglu S, et al. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol. 2012;138:1155–63. · doi:10.1007/s00432-012-1187-1
- Ko C, Shen S, Yang L, Lin C, Chen Y. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells. Int J Cancer. 2007;121:1670–9. · doi:10.1002/ijc.22910
- Yuan H, Zhou W, Yang Y, Xue L, Liu L, Song Y. ISG15 promotes esophageal squamous cell carcinoma tumorigenesis via c-MET/Fyn/β-catenin signaling pathway. Exp Cell Res. 2018;367:47–55. · DOI
- Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91–5. · DOI · Paper page
- Zhao Z, Li L, Du P, Ma L, Zhang W, Zheng L, et al. Transcriptional downregulation of miR-4306 serves as a new therapeutic target for triple negative breast cancer. Theranostics. 2019;9:1401–16. · DOI
- Capaci V, Bascetta L, Fantuz M, Beznoussenko GV, Sommaggio R, Cancila V, et al. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat Commun. 2020;11:3945. · DOI · Paper page
- Chen Z, Chen X, Xie R, Huang M, Dong W, Han J, et al. DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression. Mol Ther. 2019;27:326–41. · DOI
- Ruzzenente B, Metodiev MD, Wredenberg A, Bratic A, Park CB, Cámara Y, et al. LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs. EMBO J. 2012;31:443–56. · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Metadata
- Authors
- Yang, Y., Yuan, H., Zhao, L., Guo, S., Hu, S., Tian, M., Nie, Y., Yu, J., Zhou, C., Niu, J., Wang, G., & Song, Y.
- Venue
- Cell Death & Differentiation
- Published
- 2022-04-28
- Volume
- 29
- Issue
- 11
- Pages
- 2177-2189
- ISSN
- 1350-9047
- 1476-5403
- Cited by
- 81
- References
- 7
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- National Natural Science Foundation of China (81872398)
- National key research and development program of China
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. https://app.cochat.ai/papers/10.1038/s41418-022-01007-x
- The paper
- Yang, Y., Yuan, H., Zhao, L., Guo, S., Hu, S., Tian, M., Nie, Y., Yu, J., Zhou, C., Niu, J., Wang, G., & Song, Y. (2022). Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death & Differentiation. https://doi.org/10.1038/s41418-022-01007-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.